Description     Claims     Drawing  

WO0009558A   [0006] 
WO0009543A   [0006] 
WO9964442A   [0006] 
WO9907733A   [0006] 
WO9907734A   [0006] 
WO9950230A   [0006] 
WO9846630A   [0006] 
WO9817679A   [0006]  [0573] 
WO9743310A   [0006] 
US5990276A   [0006] 
US3840556A   [0032] 
US3719667A   [0032] 
US5807876A   [0546] 
US4835168A   [0579] 
US6127422A   [0579] 

Natural History of Hepatitis C   [0003] 
Hepatitis C Virus Infection in the United States   [0003] 
Global Surveillance and Control of Hepatitis C   [0003] 
Genetic Organization and Diversity of the Hepatitis C Virus   [0004] 
Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis   [0004] 
Structure and Organization of the Hepatitis C Virus Genome Isolated From Human Carriers   [0004] 
Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions   [0004] 
Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites   [0004] 
Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products   [0004] 
NS3 is a serine protease required for processing of hepatitis C virus polyprotein   [0004] 
Hepatitis C Virus NS3 Serine Proteinase: Trans-Cleavage Requirements and Processing Kinetics   [0004] 
Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein   [0005] 
Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3'-nontranslated region are essential for virus replication in vivo.   [0005] 
Bioorg. Med. Chem. Lett.   [0006] 
Bioorg. Med. Chem. Lett.   [0006] 
Bioorg. Med. Chem. Lett.   [0006] 
Bioorg. Med. Chem. Lett.   [0006] 
Bioorg. Med. Chem. Lett.   [0006] 
Hepatitis C Virus: an Overview of Current Approaches and Progress   [0007] 
Current and Evolving Therapies for Hepatitis C   [0007] 
Suicide Associated with Alfa-Interferon Therapy for Chronic Viral Hepatitis   [0007] 
Side effects of alpha interferon   [0007] 
Interferon Therapy in Chronic Hepatitis C Virus Infection   [0007] 
Application of a New Approach for the Quantitation of Drug Synergism to the Combination of cis-Diamminedichloroplatinum and 1-ß-D-Arabinofuranosylcytosine   [0027] 
Annual Reports in Medicinal Chemistry   [0030] 
Application Of Bioisosterism To New Drug Design   [0030] 
Bioisosteric Replacement And Development Of Lead Compounds In Drug Design   [0030] 
Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres   [0030] 
Protective Groups in Organic Chemistry   [0032] 
Protective Groups in Organic Synthesis   [0048]  [0049] 
Nomenclature of α-Amino Acids (Recommendations, 1974   [0050] 
Protective Groups in Organic Chemistry   [0051]  [0226] 
Encyclopedia of Pharmaceutical Technology   [0100] 
J. Org. Chem.   [0101] 
Design of Prodrugs   [0105] 
Methods in Enzymology   [0105] 
Design and Applications of Prodrugs   [0105] 
Advanced Drug Delivery Reviews   [0105] 
J. Pharm. Sci.   [0105] 
Chem. Pharm. Bull.   [0105] 
A.C.S. Symposium Series, and Bioreversible Carriers in Drug Design   [0105] 
Pharmaceutical Salts   [0106] 
Tetrahedron Letter   [0216] 
J. Am. Chem. Soc.   [0216] 
Synlett   [0217] 
J. Org. Chem.   [0217] 
Protective Groups in Organic Synthesis   [0218]  [0221] 
J. Org. Chem.   [0220] 
J. Org. Chem.   [0220] 
J. Org Chem.   [0221] 
The organic Chemistry of β-Lactams   [0223] 
Protective Groups in Organic Chemistry   [0226] 
Tetrahedron   [0301] 
Tetrahedron   [0311] 
J. Med. Chem.   [0472]  [0474] 
Remington's Pharmaceutical Sciences   [0556] 
Biochim. Biophys. Acta   [0574] 
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C   [0577] 
Efficacy of consensus interferon m the treatment of chronic hepatitis C   [0577] 
IFN-tau, a new interferon type I with antiretroviral activity   [0577] 
Future options for the management of hepatitis C   [0577]  [0577]  [0577]  [0577] 
Russian Experience in Screening, Analysis, and Clinical Application of Novel Interferon Inducers   [0578] 
Immunomodulatory and pharmacologic properties of imiquimod   [0578] 
The roles of amantadine, rimantadine, ursodeoxycholic acid, NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C   [0579] 
Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt   [0579] 
Goodman & Gilman's The Pharmacological Basis of Therapeutics   [0580] 
Goodman & Gilman's The Pharmacological Basis of Therapeutics   [0580] 
Acta Biochim. Pol.   [0584] 
Swed. Nucleosides Nucleotides   [0584] 
Synthesis   [0584] 
Carbohyd. Chem.   [0584] 
Chem. Nucleosides Nucleotides   [0584] 
Ann. Reports in Med. Chem.   [0584] 
Exp. Opin. Invest. Drugs   [0584] 
Hepatology   [0587] 
Chronic Hepatitis C Current Disease Management   [0592] 
Science   [0593]  [0595] 
Cancer Res.   [0595] 
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line   [0599]  [0600] 
Die Quantitation Probleme der Pharmakologic   [0620] 
The expected effect of a combination of agents: the general solution   [0622] 
Application of a New Approach for the Quantitation of Drug Synergism to the Combination of cis-Diamminedichloroplatinum and 1-β-D-Arabinofuranosylcytosine   [0622] 
Measurement of potencies of drug mixtures   [0626] 
Transformation and Weighting in Regression   [0627] 
Radioligand Assay   [0627] 
Guidelines for Immunoassay Data Processing   [0627] 
Application of a New Approach for the Quantitation of Dmg Synergism to the Combination of cis-Diamminedichloroplatinum and 1-β-D-Arabinofuranosylcytosine   [0633] 
A three-dimensional model to analyze drug-drug interactions (review   [0633] 
Efficient Initiation of HCV RNA Replication in Cell Culture   [0635] 
Hepatitis C virus replication is directly inhibited by IFN-α in a full-length binary expression system   [0635] 
Adverse effects and other safety aspects of the hepatitis C antivirals   [0635] 
Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes   [0636] 
An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT   [0636] 
Comparative quantification of IL-1beta, IL-10, IL-10r, TNFalpha and IL-7 mRNA levels in UV-irradiated human skin in vivo   [0636] 
Chronic Hepatitis C: Current Disease Management   [0640]  [0640]